Online citations, reference lists, and bibliographies.
← Back to Search

Cyclosporine A-Nanosuspension: Formulation, Characterization And In Vivo Comparison With A Marketed Formulation

M. Nakarani, P. Patel, J. Patel, P. Patel, R. Murthy, Subhash S. Vaghani
Published 2010 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Cyclosporine A-nanosuspensions were prepared using zirconium oxide beads as a milling media, Poloxamer 407 as a stabilizer and distilled water as an aqueous medium using the Pearl Milling technique. The optimized formulation was characterized in terms of particle size distribution, surface morphology, drug-surfactant interaction, drug content, saturation solubility, osmolarity, and stability. The nanoparticles consisting of Poloxamer-bound cyclosporin A with a mean diameter of 213 nm revealed a spherical shape and 5.69 fold increased saturation solubility as compared to the parent drug. The formulation was found to be iso-osmolar with blood and stable up to 3 months at 2–8°C. In-vivo studies were carried out in albino rats and the pharmacokinetic parameters were compared with a marketed formulation, which indicated better results of the prepared formulation than the marketed one.
This paper references
10.1016/J.JCONREL.2004.02.028
Synergistic penetration enhancement effect of ethanol and phospholipids on the topical delivery of cyclosporin A.
D. Verma (2004)
10.1016/S0378-5173(98)00066-0
Oral administration of liposomes containing cyclosporine: a pharmacokinetic study
M. Al-Meshal (1998)
Targeted and Controlled Drug Delivery, Novel Carrier Systems. 1 ed
SP Vyas (2002)
10.1016/j.ijpharm.2009.01.024
Diclofenac nanosuspensions: influence of preparation procedure and crystal form on drug dissolution behaviour.
F. Lai (2009)
Formulation, Characterization and In Vivo Comparison with … 361 Sci Pharm
A Cyclosporine (2010)
10.1016/0378-5173(89)90069-0
The effect of particle size distribution on dissolution rate and oral absorption
R. J. Hintz (1989)
Sci Pharm
(2010)
10.1016/S0169-409X(97)90003-X
Adv. Drug Delivery Rev.
F. Welt (1997)
10.1016/J.JBIOTEC.2004.06.007
Challenges and solutions for the delivery of biotech drugs--a review of drug nanocrystal technology and lipid nanoparticles.
R. H. Muller (2004)
10.1016/J.EJPB.2005.05.009
Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation.
C. Keck (2006)
10.2147/IJN.S595
Nanocrystal technology, drug delivery and clinical applications
Jens-Uwe A. H. Junghanns (2008)
J Biotechnol
(2004)
Formulation, Characterization and In Vivo Comparison with … 359 Sci Pharm
A Cyclosporine (2010)
Cyclosporin-containing pharmaceutical composition
Jw Kim (1999)
10.1016/S0378-5173(99)00260-4
Pharmacokinetics and organ distribution of cyclosporin A incorporated in liposomes and mixed micelles.
M. Lee (1999)
10.1016/s0939-6411(00)00091-6
Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards
R. Löbenberg (2000)
10.1023/A:1014276917363
Production and Characterization of a Budesonide Nanosuspension for Pulmonary Administration
C. Jacobs (2004)
Pharmacokinetic behavior of Cyclosporine A in rabbits by oral administration of lecithin vesicle and sandimmune neoral
J Guo (2001)
10.1023/A:1016212804288
A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability
G. Amidon (2004)
Nanosuspension: Formulation, Characterization and In Vivo Comparison with … 361
A Cyclosporine
10.1016/S0168-3659(02)00239-0
Investigation of the factors influencing the release rates of cyclosporin A-loaded micro- and nanoparticles prepared by high-pressure homogenizer.
W. Lee (2002)
10.1016/S1461-5347(00)00255-8
Therapeutic applications of colloidal drug carriers.
Barratt (2000)
Targeted and Controlled Drug Delivery
S P Vyas (2002)
10.1016/S0378-5173(00)00680-3
Pharmacokinetic behavior of cyclosporin A in rabbits by oral administration of lecithin vesicle and Sandimmun Neoral.
J. Guo (2001)
10.1016/S0928-0987(00)00181-0
In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs.
J. Dressman (2000)
10.1093/ajhp/42.5.1206
Pharmaceutical Statistics: Practical and Clinical Applications
M. Montagne (1985)
10.1016/0378-5173(95)00148-C
Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats
G. Liversidge (1995)
10.1016/J.IJPHARM.2006.02.045
Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals.
R. Mueller (2006)
Characterization of 5-fluorouracil microspheres for colonic drug
Z Rahman (2006)
10.1016/S0378-5173(97)00311-6
Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique
R. Mueller (1998)
10.1016/S0169-409X(01)00105-3
Solid lipid nanoparticles: production, characterization and applications.
W. Mehnert (2001)
10.1093/JAC/45.1.77
Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection.
K. Peters (2000)
10.1016/0378-5173(95)00122-Y
Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs
G. Liversidge (1995)
10.1016/S0939-6411(00)00091-6
Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards.
R. Löbenberg (2000)
10.1016/J.JCONREL.2004.01.017
Preparation of biodegradable cyclosporine nanoparticles by high-pressure emulsification-solvent evaporation process.
J. Jaiswal (2004)
Controlled drug delivery with nanoparticles : current possibilities and future trends
P. Couvreur (1995)
10.1016/S0928-0987(02)00057-X
Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen.
R. Pignatello (2002)
Handbook of Pharmaceutical Excipients
Pharmaceutical Press (2012)
10.1016/S0378-5173(02)00040-6
Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability.
R. Mueller (2002)
10.1208/ps040440
An in vitro examination of the impact of polyethylene glycol 400, pluronic P85, and vitamin E d-a-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine
B. Johnson (2008)
10.1016/j.addr.2007.11.008
Suspensions for intravenous (IV) injection: a review of development, preclinical and clinical aspects.
J. Wong (2008)
10.1016/S0378-5173(03)00356-9
Targeted and Controlled Drug Delivery: Novel Carrier Systems
A. Florence (2003)
10.1016/S1461-5347(99)00177-7
Lab-scale production unit design for nanosuspensions of sparingly soluble cytotoxic drugs.
Boehm (1999)
Int J Pharm
(2006)
New Delhi: CBS Publishers
(2002)
Nanosuspension: Formulation, Characterization and In Vivo Comparison with … 359
A Cyclosporine



This paper is referenced by
DESIGN AND EVALUATION OF SOLID LIPID NANOPARTICLES OF TAMOXIFEN CITRATE BY FACTORIAL DESIGN
B. Basu (2012)
10.1016/j.ijpharm.2012.09.034
Drug nanocrystals in the commercial pharmaceutical development process.
J. Möschwitzer (2013)
Nanosuspension – A Novel Carrier For Lipidic Drug Transfer
Abhyangshree Nandkumar Mane (2014)
10.1007/s40005-013-0051-x
Nanosuspensions: a new approach for organ and cellular targeting in infectious diseases
Shegokar Ranjita (2013)
10.2147/IJN.S27830
Comparative manufacture and cell-based delivery of antiretroviral nanoformulations
Shantanu S Balkundi (2011)
10.1016/j.ejps.2012.09.015
Development and evaluation of PIK75 nanosuspension, a phosphatidylinositol-3-kinase inhibitor.
M. Talekar (2012)
10.1016/j.jconrel.2013.08.006
Stability of nanosuspensions in drug delivery.
Y. Wang (2013)
Nanosuspension: An Assuring Novel Drug Delivery System
S. Das (2013)
10.1007/s11051-014-2360-z
Formulation, optimization, and in vitro/in vivo evaluation of furosemide nanosuspension for enhancement of its oral bioavailability
B. Sahu (2014)
NANOSUSPENSION : BIOAVAILABILITY ENHANCING NOVEL APPROACH
B. S. Nayak (2018)
10.1007/s40011-012-0080-7
Drug Delivery Using Nanocarriers: Indian Perspective
S. Gupta (2012)
10.1080/01932691.2011.590424
Preparation and Characterization of Ursodeoxycholic Acid Nanosuspension
Peng-fei Yue (2012)
10.1016/J.POWTEC.2014.03.001
Design and development of solid nanoparticulate dosage forms of telmisartan for bioavailability enhancement by integration of experimental design and principal component analysis
J. Patel (2014)
10.1208/s12248-016-0039-3
Porous mannitol carrier for pulmonary delivery of cyclosporine A nanoparticles
S. Leung (2016)
10.1088/1742-6596/418/1/012149
Enhancing effect of negative polypropylene electret on in vitro transdermal delivery of cyclosporine A solution and its synergistic effect with ethyl oleate
Cui Longjiu (2013)
10.1007/978-3-319-41421-8_13
Associating Drugs with Polymer Nanoparticles: A Challenge
C. Zandanel (2016)
10.1016/J.JDDST.2016.10.009
Preparation and characterization of a lutein loading nanoemulsion system for ophthalmic eye drops
Chaemin Lim (2016)
A New Emerging Technique for Biovailability Enhancement
Bhatt Ganesh (2013)
Pharmacological screening of self-emulsifying drug delivery system containing cyclosporine for solubility enhancement
Ashok Kumar Rajpoot (2019)
10.1016/j.ejpb.2014.08.013
Dissolution enhancement and in vitro performance of clarithromycin nanocrystals produced by precipitation-lyophilization-homogenization method.
Boontida Morakul (2014)
NANOSUSPENSION OF A DRUG AND ITS BIOLOGICAL ACTIVITY- A REVIEW
S. Nair (2016)
10.1007/978-3-319-41421-8_14
Drug Delivery by Polymer Nanoparticles: The Challenge of Controlled Release and Evaluation
C. Charrueau (2016)
FORMULATION OF NANOSUSPENSION AND NANOEMULSION AS A NEW APPROACHFOR THE DELIVERY OF POORLY SOLUBLE DRUGS
O. Bhusnure (2015)
10.4172/2325-9604.1000175
Application of Acoustic- Vibratory Milling For Screening and Scale-Up of Micro/ Nanosuspensions in Early Drug Discovery and Development
Hoang D. Lu (2018)
Effect of hydrophobic nanoparticle cores on the characteristics of poly ( ε-caprolactone )-cod-α-tocopheryl polyethylene glycol 1000 succinate nanoparticles loaded with camptothecin
Y. Sirithananchai (2015)
NANOSUSPENSION: A NOVEL APPROACH TOWARDS THE DRUG DELIVERY SYSTEM
Shailesh U. Ginoya (2013)
10.25004/IJPSDR.2017.090403
Formulation and Optimization of Nanosuspension Prepared By Media Milling Technique to Enhance the Solubility of Isradipine
Umang Motka (2017)
10.22159/IJAP.2017V9I6.21674
FORMULATION AND EVALUATION OF POLYMERIC NANOSUSPENSION OF NARINGENIN
R. Sumathi (2017)
10.12691/NNR-4-2-4
Nanosuspension Technologies for Delivery of Drugs
Sachin S.Pawar (2017)
10.1021/mp5008376
Comparative Biodistribution and Pharmacokinetic Analysis of Cyclosporine-A in the Brain upon Intranasal or Intravenous Administration in an Oil-in-Water Nanoemulsion Formulation.
S. Yadav (2015)
10.18433/jpps30245
Development, Characterization, and Pharmacokinetic Evaluation of a CRV431 Loaded Self-Microemulsifying Drug Delivery System.
Daniel J. Trepanier (2018)
10.37285/ijpsn.2014.7.4.7
Formulation and Evaluation of Nanosuspension Formulation for Drug Delivery of Simvastatin
Rupali L. Shid (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar